SCS Platform Advantage Clearside focuses on suprachoroidal space (SCS) delivery and has developed the SCS Microinjector for in-office, non-surgical administration. This creates a differentiator in ocular drug delivery and suggests sales opportunities with pharma and biotech firms seeking targeted back-of-eye therapies.

Pipeline & Partnerships The company is building its own small molecule pipeline for SCS administration while also partnering the delivery platform with others’ ophthalmic therapies. This signals multiple BD angles: license or co-development discussions, and collaboration opportunities for companies with complementary pipelines.

Regulatory Milestone XIPERE received FDA approval in October 2021, establishing a regulatory track record for suprachoroidal delivery. This history can bolster conversations with eye-care clinicians and payers, highlighting a validated delivery route and potential market access benefits.

Clinical Engagement Frequent participation in ophthalmology conferences and ARVO abstracts indicates active clinician and researcher engagement. Opportunities exist to propose sponsored studies, investigator-initiated trials, or real-world data collaborations to expand evidence for SCS delivery.

Growth & Financials Revenue is in the low single digits with a lean team, suggesting a nimble organization open to strategic partnerships, distribution deals, and sales channels with larger ophthalmic players to scale adoption of SCS-based therapies.